Banco Bilbao Vizcaya Argentaria S.A. Decreases Stock Position in Pfizer Inc. $PFE

Banco Bilbao Vizcaya Argentaria S.A. cut its position in Pfizer Inc. (NYSE:PFE) by 31.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,203,350 shares of the biopharmaceutical company’s stock after selling 564,462 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Pfizer were worth $29,974,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in PFE. Horizon Financial Services LLC grew its holdings in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new position in Pfizer during the fourth quarter worth about $26,000. YANKCOM Partnership acquired a new position in Pfizer during the fourth quarter worth about $28,000. HFM Investment Advisors LLC grew its stake in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Abound Financial LLC acquired a new stake in Pfizer in the 4th quarter valued at about $31,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PFE. UBS Group restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. Citigroup lifted their price objective on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Finally, Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.82.

Pfizer Trading Down 0.3%

PFE opened at $25.95 on Thursday. The stock has a market capitalization of $147.89 billion, a PE ratio of 19.81 and a beta of 0.34. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The business’s 50 day moving average price is $26.30 and its 200 day moving average price is $26.34.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the business earned $0.92 earnings per share. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date was Friday, May 8th. Pfizer’s payout ratio is 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.